NeoImmuneTech

NeoImmuneTech (NIT), founded in 2014, is a clinical-stage T cell-focused biotechnology company dedicated to the discovery and development of novel immunotherapies. At NIT, we strive to expand the therapeutic landscape of immuno-oncology and infectious diseases by significantly reducing the mortality and morbidity of life-threatening and debilitating diseases. Guided by our scientific founder, who invented our lead asset NT-I7 (efineptakin alfa), we are science-driven and patient-centric. We believe NT-I7 is the only clinical-stage IL-7 that can enhance the body’s immune function to address key resistance mechanisms in immuno-oncology and life-threatening infectious diseases.